Fast track — ArticlesEffects of pravastatin in 3260 patients with unstable angina: results from the LIPID study*
Introduction
The number of patients with unstable angina who require admission to monitored beds for hospital treatment is increasing and, in many countries, is higher than the number of patients admitted with acute myocardial infarction.1 However, although these patients have similar pathophysiology,2 scientific data relating to the long-term prevention of further coronary-heart-disease events has generally been limited to the patients with myocardial infarction. For patients with unstable angina, the place of cholesterol-lowering therapy for secondary prevention of coronary-heart-disease events has had little attention.
Overall results in the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study—the largest trial of lipid-modifying therapy with a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor—have been presented.3 This is the only trial of prevention to include patients admitted to hospital with unstable angina as well as those with previous myocardial infarction. The trial design included stratification by this qualifying diagnosis, since whether the effects of treatment would be the same in both groups of patients was not known.
In this substudy, our objectives were: (1) to ascertain the long-term risks of major cardiovascular events in patients qualifying for the LIPID study with unstable angina; (2) to compare the risks of major cardiovascular events in patients qualifying with unstable angina with those in patients who had had myocardial infarction; and (3) to compare the effects of pravastatin in the patients with previous unstable angina with those in the patients with previous acute myocardial infarction.
Section snippets
Patients
The design of the LIPID study has been described in detail elsewhere.4 9014 patients (7498 men and 1516 women, aged 31–75 years) were recruited in 87 centres in Australia and New Zealand between June, 1990, and December, 1992. Patients had had an acute myocardial infarction or a hospital discharge diagnosis of unstable angina 3–36 months before randomisation. Patients who had experienced both acute myocardial infarction and hospital admission for unstable angina within this period were included
Results
We studied3260 patients (2605 men, 655 women) with unstable angina, which occurred a median of 18·8 months (IQR 8·6–36·7) previously, and 5754 (4893 men, 861 women) who had had acute myocardial infarction a median of 14·6 months (8·2–25·8 months) previously.
There were differences in the baseline characteristics of these groups (table 1). Those stratified by the diagnosis of unstable angina included a higher proportion of women, and on average, were slightly older than the patients who had had
Discussion
The results of the LIPID study show that patients who have survived acute myocardial infarction and those who have survived unstable angina have a similar long-term prognosis, although this may have been influenced by selection criteria, such as exclusion of patients with poor left-ventricular function. Although there were differences in some risk factors at baseline, these factors were well balanced by treatment within these groups, and they did not affect the analysis of the effects of
References (22)
- et al.
HMG-CoA reductase inhibitors decrease CDIIb expression and CDIIb-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolaemia
J Am Coll Cardiol
(1997) Evidence for the benefit of early intervention with pravastatin for secondary prevention of cardiovascular events
Atherosclerosis
(1999)- et al.
Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction
Am J Cardiol
(1998) - et al.
Acute coronary syndromes. Unstable angina and non-Q wave myocardial infarction
Circulation
(1998) Molecular bases of the acute coronary syndromes
Circulation
(1995)Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
N Engl J Med
(1998)Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischaemic Disease) Study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris
Am J Cardiol
(1995)- et al.
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
Clin Chem
(1972) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Lancet
(1994)- et al.
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
N Engl J Med
(1996)
Unstable angina: diagnosis and management. Clinical Practice Guideline Number 10, AHCPR publication 94-0602
Cited by (78)
Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis
2016, AtherosclerosisCitation Excerpt :Finally, 88 studies were included (Supplemental Fig. 1). Of the 88 studies, 34 studies [24–57] reported TC, 45 studies [24–54,56–69] reported LDL-C, 33 studies [24,26–33,35–38,40–46,48,49,51–53,55–57,59,62,64,68,69] reported HDL-C, 34 studies [24,26–33,35–38,40,42–57,62,64,68,69] reported TG, 13 studies [25,39,40,50,63,66,70–76] reported AE, 67 studies [24–27,29–39,41–45,59–63,65–67,70–108] reported CHD mortality and 55 studies [25–29,31–35,38–41,44,59–62,66,69–83,85,86,90–92,94–96,98–100,103–111] reported all-cause mortality. The characteristics of eligible studies are summarized in Table 1.
Lipoprotein Metabolism and the Treatment of Lipid Disorders
2015, Endocrinology: Adult and PediatricAccuracy of national mortality codes in identifying adjudicated cardiovascular deaths
2011, Australian and New Zealand Journal of Public Health
- *
Deceased